2005 Coronavirus vaccine promising in SARS prevention

1 Pages·2005·0.13 MB·English

Inpharma 1469 - 8 Jan 2005

■
Sinovac’s coronavirus vaccine* induces
coronavirus-neutralising antibodies and is a promising
development in SARS prevention,** according to
preliminary results from a phase I study. In this study,
36 healthy volunteers were randomised to receive two
doses of a coronavirus vaccine (n = 24) or placebo,
28 days apart. After the preliminary 56-day
observation period, blood serum conversion was
observed in 11 of 12 and 12 of 12 subjects who
received high and low doses of the vaccine,
respectively. The antibody serum conversion rates
were 50% and 100% at days 35 and 42, respectively.

* Sinovac Biotech; phase I for coronavirus infections in China
** severe acute respiratory syndrome

Sinovac Biotech Ltd. Sinovac Biotech Ltd. Releases Further Results From
SARS Vaccine Phase I Human Clinical Trial. Media Release : 13 Dec 2004.
Available from: URL: http://www.sinovac.com
809042979

1

Inpharma 8 Jan 2005 No. 1469
1173-8324/10/1469-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved